Results 1 to 10 of about 682 (125)

Advances in the effectiveness and safety of azvudine treatment: a comprehensive review [PDF]

Frontiers in Pharmacology
The global impact of COVID-19 has highlighted the urgent need for effective therapeutic interventions against SARS-CoV-2. Azvudine, a dual-target nucleoside drug initially developed for human immunodeficiency virus (HIV), has gained attention for its ...
Junbiao Chang, Zheyi Dong, Wenge Li
exaly   +6 more sources

Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study

Acta Pharmaceutica Sinica B, 2023
In our retrospective cohort study, we aim to explore whether Azvudine modifies the risk of death in COVID-19 patients. It was conducted on the medical records of patients, consecutively admitted for COVID-19 pneumonia to two hospitals in Chongqing, China.
Kaican Zong, Hui Zhou, Wen Li, E Jiang, Yi Liu, Shiying Li   +5 more
exaly   +5 more sources

Effectiveness and Safety of Oral Azvudine for Elderly Hospitalized Patients With COVID‐19: A Multicenter, Retrospective, Real‐World Study [PDF]

Advanced Science
Azvudine is recommended as a priority treatment for patients with Coronavirus Disease 2019 (COVID‐19) during Omicron wave in China, but its efficacy and safety in elderly patients is unknown.
Ranran Sun, Haiyu Wang, Junyi Sun, Mengzhao Yang, Shixi Zhang, Xinjun Hu, Bo Yu, Zhan Song, Na Han, Hong Luo, Ming Cheng, Guangming Li, Guotao Li, Yiqiang Yuan, Lili Liang, Yanyang Zhang, Donghua Zhang, Silin Li, Quancheng Kan, Hongxia Liang, Zhigang Ren   +20 more
doaj   +3 more sources

The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS‐CoV‐2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study [PDF]

Advanced Science
Despite azvudine being prioritized for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, its effectiveness and safety remain inadequately substantiated in hospitalized SARS‐CoV‐2 infected patients with liver ...
Junyi Sun, Mengzhao Yang, Guanyue Su, Ling Wang, Xiaobo Hu, Yongjian Zhou, Guangying Cui, Guowu Qian, Yiqiang Yuan, Xinjun Hu, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Ming Cheng, Zujiang Yu, Zhigang Ren   +18 more
doaj   +3 more sources

Impact of early and delayed azvudine administration on COVID-19 mortality: a retrospective study [PDF]

Scientific Reports
Azvudine is recommended for patients with coronavirus disease 19 (COVID-19); however, its optimum therapeutic time window and its impact on mortality of patients are unclear.
Luo Wang, Yaqi Wang, Yan Xu, Junping Fan, Siqi Pan, Huaiya Xie, Ting Zhang, Ruxuan Chen, Xiaoyan Liu, Chuan Shi, Qing Zhou, Yuequan Shi, Chongsheng Cheng, Lu Dai, Haoran Zhang, Aohua Wu, Xueqi Liu, Hong Zhang, Jinglan Wang, Bin Du, Jihai Liu, Huadong Zhu, Xiaojun Ma, Jing Huang, Xinlun Tian, Mengzhao Wang, Shuyang Zhang   +26 more
doaj   +4 more sources

Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19 [PDF]

Scientific Reports
Cancer significantly contributes to the unfavorable prognosis of coronavirus disease 2019 (COVID-19) patients. The efficacy and safety of azvudine and nirmatrelvir/ritonavir (Paxlovid) in cancer patients with COVID-19 remain uncertain.
Bohan Jia, Junyi Sun, Di Zhu, Ling Wang, Xiaobo Hu, Haiyu Wang, Guowu Qian, Donghua Zhang, Silin Li, Hong Luo, Shixi Zhang, Guotao Li, Guangming Li, Hongxia Liang, Zujiang Yu, Zhigang Ren   +15 more
doaj   +4 more sources

Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19 [PDF]

BMC Infectious Diseases
Purpose To compare the effectiveness and safety of two antiviral drugs, azvudine and nirmatrelvir/ritonavir, in treating hospitalized patients with COVID-19.
Jin Yang, Jiao Min, Ling Ding, Rong Liu, Ya Yang, Jian-feng Zhang, Wei Lei   +6 more
doaj   +4 more sources

Real-World Evaluation Study of Azvudine for the Treatment of Patients With COVID-19: A Systematic Review and Meta-Analysis [PDF]

Canadian Journal of Infectious Diseases and Medical Microbiology
Conclusions: Azvudine significantly reduced the hospitalization time and the time to nucleic acid conversion to negative in COVID-19 patients and significantly lowered all-cause mortality (Grading of Recommendations Assessment, Development, and ...
Abiden Kapar, Huling Li, Qian He, Dandan Lin, Dandan Tang, Kai Peng, Yida Wang, Kai Wang   +7 more
doaj   +3 more sources

Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis

Heliyon, 2023
Introduction: Azivudine has undergone a few randomized controlled trials (RCTs) as of late. This study aimed to assess the COVID-19 treatment with azvudine's efficacy and safety.
Zhaoyan Chen, Fangyuan Tian
exaly   +5 more sources

Adherence and recommended optimal treatment to Azvudine application for the treatment of outpatient COVID-19 patients: A real-world retrospective study [PDF]

Heliyon
Background: Azvudine was approved for the treatment of coronavirus disease 2019 (COVID-19) in China and has been widely used since the outbreak in December 2022. However, real-world research on the adherence of Azvudine is lacking.
Hui Yang, Ying Zhang, Zhaojian Wang, Man Xu, Yushu Wang, Yi Zhang, Xin Feng, Zhuoling An   +7 more
exaly   +4 more sources